Aaron Xin is a senior legal consultant in O’Melveny’s Shanghai office. He has worked in the areas of compliance, investigations, capital markets, private equity, and foreign direct investment transactions across various industries in China.
CapsoVision, Inc. (NASDAQ: CV) in its approximately US$27.5 million IPO and listing on NASDAQ
Tianhui Biotech in the US$75 million NewCo model investment with Oramed
eHi Car Services Limited in:
US$120 million IPO and listing on the NYSE
US$325 million Regulation S high-yield bond offering due 2027
US$152 million bond exchange offer and exit consent solicitation
Adlai Nortye Ltd. (NASDAQ: ANL) in its approximately US$100 million IPO on the Nasdaq
A buyer consortium led by Fang Holdings (OTC: SFUNY) in a going private transaction involving China Index Holdings (NASDAQ: CIH) valued at approximately US$92 million
A buyer consortium in the going private transaction of 111, Inc. (NASDAQ:YI)
OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
Citi Group and Morgan Stanley as representatives of the underwriters in the US$183 million follow-on offering of UP Fintech Holding Limited (Nasdaq: TIGR)
A buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group in a “going private” transaction valued at approximately US$380 million
Phoenix Media in its US$80 million acquisition of Publication International Ltd.’s Children’s book business
Xitogen Technologies, a start-up company engaging in sales of new generation flow cytometers in connection with its sale to Danaher Corporation, a global Fortune 200 company headquartered in Washington, DC
Shanghai Pudong Science & Technology Investment Co., Ltd., a Shanghai-based state-owned investment management company in:
its acquisition of 14.9% equity interests in LightPath Technologies, Inc., a US-based Nasdaq-listed leading manufacturer of proprietary optical components
the Series G financing of VeriSilicon Holdings Co., Ltd., a leading IC design company
Asieris Medical Technologies Co., Ltd., a start-up new generation anti-cancer drug developer, and its onshore affiliate in connection with their Series B financing
Founders of a leading Chinese vocational education group, 7 Days Group Holdings Limited, a leading hotel chain company, the independent committee of ShangPharma Corporation, a leading pharmaceutical research outsourcing company, and the independent committee of Feihe International, Inc., a leading infant formula producer in their respective “going-private” transactions
Christine International Holdings Limited, a leading bakery chain operator, in its HK$400 million IPO
A leading multi-brand B2C online retailer of fashion apparel in China in its proposed US IPO and a leading developer, manufacturer, and distributor of medical equipment in China in its proposed HK IPO
One of the largest corporate conglomerates in Japan in its acquisition of a car rental company in China
The online sales business arm of a Chinese state-owned food processing holding company in connection with its proposed acquisition of a Shanghai-based online seller of high-quality food
A leading developer, manufacturer, and distributor of medical equipment and a rapidly growing agricultural company in China in their US class action lawsuit and SEC investigation
A global leader in consumer electronics in its FCPA investigation and other internal anti-corruption investigation
A leading search engine company in the liquidation of its wholly owned subsidiary in China
A leading foreign-invested plastic package producer in its condemnation and relocation disputes